Professur für Molekulare Mechanismen der Organfibrose

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial (2021) Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Journal article cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis (2020) Worrell JC, Leslie J, Smith GR, Zaki MYW, Paish HL, Knox A, James ML, et al. Journal article A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease (2020) González-Serna D, Ochoa E, López-Isac E, Julià A, Degenhardt F, Ortego-Centeno N, Radstake TR, et al. Journal article Reply (2020) Soare A, Distler J Journal article, Letter Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets (2020) Moinzadeh P, Kuhr K, Siegert E, Mueller-Ladner U, Riemekasten G, Günther C, Kötter I, et al. Journal article Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging (2020) Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, Cordes M, et al. Journal article Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib (2020) Matteson E, Distler O, Distler J, Kuwana M, Pope J, Seibold J, James A, et al. Conference contribution NR4A1 AGONIST CYTOSPORONE B DOES NOT ATTENUATE CAV IN A MOUSE MODEL DESPITE REPORTED ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY EFFECTS (2020) Kuckhahn A, Ramsperger-Gleixner M, Distler J, Weyand M, Heim C Conference contribution Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Matei AE, Zhou X, et al. Journal article Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function (2020) Wuyts WA, Azuma A, Distler J, Sondergaard K, Proudman S, Cottin V, Erhardt E, et al. Conference contribution